Reuters logo
BRIEF-Roche CEO says Aphinity study impact on Perjeta sales not seen until 2018
April 27, 2017 / 6:43 AM / 8 months ago

BRIEF-Roche CEO says Aphinity study impact on Perjeta sales not seen until 2018

April 27 (Reuters) - Roche Holding Ag’s

* CEO Severin Schwan says Ocrevus launch off to a very good start

* Roche expects competition from Rituxan biosimilars in second quarter, Herceptin biosimilars in the second half

* Drug chief Dan O‘Day says remains confident with the totality of our portfolio that we can offset the introduction of biosimilars

* Schwan says aphinity study’s impact on perjeta sales not seen until 2018 Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below